Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer's disease population

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 6, 2008, Pages 822-829

  Profenno, Louis A ^a   Faraone, Stephen V ^b,c  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c Department of Neuroscience and Physiology ^*

Author keywords

Dementia; Diuretic; Insulin; Obesity

Indexed keywords

ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DEPENDENT VARIABLE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; INDEPENDENT VARIABLE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONSET AGE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; OVERWEIGHT; PREVALENCE;

EID: 51449093920     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30694     Document Type: Article

References (64)

1. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S. 2006. Diabetes mellitus and risk of developing Alzheimer disease: Results from the framingham study. Arch Neurol 63:1551-1555.
2. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. 2004. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661-666.
3. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. 1996. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 44:1147-1152.
4. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. 1994. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The national institute of mental health genetics initiative. Arch Neurol 51:1198-1204.
5. Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS, Tanzi R. 1997. ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative. Neurology 48:139-147.
6. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. 2005. Change in body mass index and risk of incident Alzheimer disease. Neurology 65:892-897.
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
8. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. 2006. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National health and nutrition examination survey 1999-2002. Diabetes Care 29:1263-1268.
9. Craft S, Watson GS. 2004. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3:169-178.
10. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ. 2003. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28:809-822.
11. Culmsee C, Monnig J, Kemp BE, Mattson MP. 2001. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 17:45-58.
12. Dixit M, Bhattacharya S, Mittal B. 2005. Association of CETP TaqI and APOE polymorphisms with type II diabetes mellitus in north Indians: A case control study. BMC Endocr Disord 5:7.
13. Eckel RH, Grundy SM, Zimmet PZ. 2005. The metabolic syndrome. Lancet 365:1415-1428.
14. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. 2004. Obesity-related leptin regulates Alzheimer's abeta. FASEB J 18:1870-1878.
15. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. 2005. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 62:1539-1544.
16. Friedman JM, Halaas JL. 1998. Leptin and the regulation of body weight in mammals. Nature 395:763-770.
17. Gasparini L, Xu H. 2003. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 26:404-406.
18. Grubber JM, Saunders AM, Crane-Gatherum AR, Scott WK, Martin ER, Haynes CS, Conneally PM, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1999. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett 269:115-119.
19. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. 1999. Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol 56:991-996.
20. Gustafson D. 2006. Adiposity indices and dementia. Lancet Neurol 5:713-720.
21. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. 2003. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163:1524-1528.
22. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L. 1975. Cerebral blood flow in dementia. Arch Neurol 32:632-637.
23. Harvey J, Shanley LJ, O'Malley D, Irving AJ. 2005. Leptin: A potential cognitive enhancer? Biochem Soc Trans 33:1029-1032.
24. Hayden KM, Zandi PP, Lyketsos CG, Tschanz JT, Norton MC, Khachaturian AS, Pieper CF, Welsh-Bohmer KA, Breitner JC, Cache County Investigators. 2005. Apolipoprotein E genotype and mortality: Findings from the cache county study. J Am Geriatr Soc 53:935-942.
25. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JC, Welsh-Bohmer KA, Cache County Investigators. 2006. Vascular risk factors for incident Alzheimer disease and vascular dementia: The cache county study. Alzheimer Dis Assoc Disord 20:93-100.
26. Hong M, Lee VM. 1997. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272:19547-19553.
27. Huber PJ. 1967. The behavior of maximum likelihood estimates under non-standard conditions. Proc Fifth Berkeley Symp Math Stat Probab 1:221-233.
28. Jefferson MF, Burlinson S, Burns A, Mann D, Pickering-Brown S, Owen F, Sriwardhana C, Pendleton N, Horan MA. 2001. Clinical features of dementia associated with apolipoprotein epsilon4: Discrimination with a neural network genetic algorithm. Int J Geriatr Psychiatry 16:77-81.
29. Khachaturian ZS. 1985. Diagnosis of Alzheimer's disease. Arch Neurol 42:1097-1105.
30. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. 2006. Antihypertensive medication use and incident Alzheimer disease: The cache county study. Arch Neurol 63:686-692.
31. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. 2005. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62:1556-1560.
32. Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, Craft S. 2006. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 66:1506-1510.
33. Kurochkin IV, Goto S. 1994. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345:33-37.
34. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, Laakso M. 1997. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. Br Med J 315:1045-1049.
35. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ. 1997. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 145:301-308.
36. Leiva E, Mujica V, Orrego R, PrietoM, Arredondo M. 2005. Apolipoprotein E polymorphism in type 2 diabetic patients of talca, Chile. Diabetes Res Clin Pract 68:244-249.
37. Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J. 2003. Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem 254:353-358.
38. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. 2001. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635-641.
39. Luchsinger JA, Tang MX, Shea S, Mayeux R. 2004. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63:1187-1192.
40. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. 2005. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65:545-551.
41. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L. 1997. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 23:47-61.
42. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34:939-944.
43. Nourhashemi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P, PAQUID study. Personnes Agees Quid. 2003. Body mass index and incidence of dementia: The PAQUID study. Neurology 60:117-119.
44. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. 1999. Diabetes mellitus and the risk of dementia: The rotterdam study. Neurology 53:1937-1942.
45. Pannacciulli N, Le DS, Chen K, Reiman EM, Krakoff J. 2006. Relationships between plasma leptin concentrations and human brain structure: A voxel-based morphometric study. Neurosci Lett 412:248-253.
46. Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. 2002. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The honolulu-asia aging study. Diabetes 51:1256-1262.
47. Raghu P, Sivakumar B. 2004. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: Implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta 1703:1-9.
48. Reger MA, Watson GS, Frey WH II, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. 2006. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging 27:451-458.
49. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer's Disease Study Group. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254.
50. Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. 2005. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 165:321-326.
51. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. 2000. Insulin receptors and insulin action in the brain: Review and clinical implications. Neurosci Biobehav Rev 24:855-872.
52. Singh PP, Naz I, Gilmour A, Singh M, Mastana S. 2006. Association of APOE (Hha1) and ACE (I/D) gene polymorphisms with type 2 diabetes mellitus in North West India. Diabetes Res Clin Pract 74:95-102.
53. Soares ML, Coelho T, Sousa A, Batalov S, Conceicao I, Sales-Luis ML, Ritchie MD, Williams SM, Nievergelt CM, Schork NJ, Saraiva MJ, Buxbaum JN. 2005. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: Complexity in a single-gene disease. Hum Mol Genet 14:543-553.
54. Spranger J, Verma S, Gohring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschop M, Banks WA. 2006. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55:141-147.
55. Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, Launer LJ. 2005. A 32-year prospective study of change in body weight and incident dementia: The honolulu-asia aging study. Arch Neurol 62:55-60.
56. Tschape JA, Hammerschmied C, Muhlig-Versen M, Athenstaedt K, Daum G, Kretzschmar D. 2002. The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and appl processing. EMBO J 21:6367-6376.
57. Unger RH. 2003. Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 14:398-403.
58. Vanhanen M, Kivipelto M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, Hanninen T, Kervinen K, Kesaniemi YA, Laakso MP, Soininen H, Laakso M. 2001. APOE-epsilon4 is associated with weight loss in women with AD: A population-based study. Neurology 56:655-659.
59. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J. 2006. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 67:843-847.
60. Wallum BJ, Taborsky GJ Jr, Porte D Jr, Figlewicz DP, Jacobson L, Beard JC, Ward WK, Dorsa D. 1987. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 64:190-194.
61. White JT, Kelly JW. 2001. Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci USA 98:13019-13024.
62. White H, Pieper C, Schmader K, Fillenbaum G. 1996. Weight change in Alzheimer's disease. J Am Geriatr Soc 44:265-272.
63. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. 2005. Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. Br Med J 330:1360.
64. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. 2004. Diabetes mellitus and risk of dementia in the kungsholmen project: A 6-year follow-up study. Neurology 63:1181-1186.